出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年2月
Contrast Media Market – Global Forecast to 2029
造影剤市場 : タイプ (ヨード造影剤)、形態 (液体、粉末)、モダリティ (X 線、CT、MRI、超音波)、投与経路 (経口、直腸)、適応症 (がん、神経疾患、消化管疾患、筋骨格系疾患) – 2029年までの世界予測
Contrast Media Market by Type (Iodinated Contrast Media), Form (Liquid, Powder), Modality (X-ray, CT, MRI, Ultrasound), Route of Administration (Oral, Rectal), Indication (Cancer, Neurological, GI, Musculoskeletal Disorders) – Global Forecast to 2029
| ページ数 | 279 |
| 図表数 | 294 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The contrast media market is valued at an estimated USD 6.3 billion in 2023 and is projected to reach USD 9.7 billion by 2029 at a CAGR of 7.5% during the forecast period.
造影剤市場は、2023 年に推定 63 億米ドルと評価され、予測期間中に 7.5% の CAGR で 2029 年までに 97 億米ドルに達すると予測されています。
Contrast media are chemical reagents that are administered to patients undergoing radiology imaging procedures to gain enhanced images and better results of the procedure. Patients with chronic conditions often require require diagnosis, imaging forms a major part of their treatment. Hence, with an increase in the prevalence of chronic conditions, the procedures that need contrast media are also expected to increase, hence enabling market growth.
“Computed Tomography (CT) segment is projected to witness highest growth rate in the contrast media market, by modality, during the forecast period.”
The contrast media market is segmented into X-ray, CT, MRI, and Ultrasound, on the basis of modality. The CT segment in contrast media is experiencing significant growth, owing to rise in the number of CT examinations that need the use of contrast media, coupled with its benefits such as, high resolution imaging, applications across broad areas such as CVD, cancer, GI diseases, and neurological conditions, among others.
“Interventional Radiology segment is projected to register highest growth rate in the contrast media market, by application, during the forecast period.”
The global contrast media market is bifurcated into radiology, interventional radiology, and interventional cardiology, based on application. The interventional radiology segment is expected to grow at the highest rate within the contrast media market. The surge in demand for interventional radiology procedures is attributed to various factors such as introduction of sophisticated technologies among CT, MRI and ultrasound modalities, coupled with rise in the preference for minimally invasive procedures for the diagnosis of various medical conditions.
“Asia Pacific: The fastest-growing region contrast media market.”
The global contrast media market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging economies in the Asia Pacific region such as China and India have been significantly investing in the development of their existing healthcare infrastructure, coupled with the rising prevalence of chronic conditions. These factors are anticipated to provide growth opportunities for contrast media companies operating in this region.
The break-up of the profile of primary participants in the contrast media market:
• By Company Type: Tier 1 – 35%, Tier 2 – 40%, and Tier 3 – 25%
• By Designation: C-level – 45%, D-level – 29%, and Others – 26%
• By Region: North America – 35%, Europe – 27%, Asia Pacific – 32%, Rest of the World- 6%
The key players in contrast media market are GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US), Unijules Life Sciences Ltd. (India), JB Pharma (India), Sanochemia Pharmazeutika (Germany), TAEJOON PHARM Co., Ltd. (South Korea), Jodas Expoim (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko Ýlaç San. ve Tic. A.Þ. (Turkey), Fresenius Kabi (Germany), Biem İlaç San. ve Tic. A.Ş. (Turkey), and AdvaCare (US).
Research Coverage:
This research report categorizes the contrast media market by type (iodinated contrast media, microbubble contrast media, gadolinium-based contrast media, and barium-based contrast media), form (liquid, powder, and other forms), modality (CT, X-ray, MRI, and ultrasound), route of administration (intravascular route, rectal route, oral route, and other routes of administration), indication (cancer, cardiovascular diseases, gastrointestinal disorders, neurological disorders, and musculoskeletal disorders, nephrological disorders), application (radiology, inteventional radiology, and interventional cardiology), end user (hospital, clinics, and ambulatory surgical centers, and diagnostics imaging centers), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the contrast media market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies; acquisitions, and partnerships. new product launches, and recent developments associated with the contrast media market. This report covers the competitive analysis of upcoming startups in the contrast media market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall contrast media market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (rising prevalence of chronic diseases, rising volume of CT and MRI examinations performed, growing number of approvals of contrast media, and rising number of diagnostic centers and hospitals), restraints (Side-effects and risks of allergic reactions associated with contrast media), opportunities (development of generic contrast media and increasing research on contrast media), and challenges (preference of alternative modalities that do not need contrast media and dearth of trained professionals) influencing the growth of the contrast media market
• Product Development/Innovation: Detailed insights on research & development activities, and new product launches and approvals in the contrast media market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the contrast media market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the contrast media market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like GE HealthCare (US), Bracco Imaging S.p.A. (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging (US) among others in the contrast media market strategies.
Table of Contents
1 INTRODUCTION 23
1.1 STUDY OBJECTIVES 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY 24
1.3 MARKET SCOPE 25
1.3.1 MARKETS COVERED 25
FIGURE 1 CONTRAST MEDIA MARKET SEGMENTATION 25
1.3.2 REGIONAL SCOPE 25
1.3.3 YEARS CONSIDERED 26
1.4 CURRENCY 26
1.5 MARKET STAKEHOLDERS 26
1.6 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 2 RESEARCH DESIGN 28
2.1.1 SECONDARY RESEARCH 29
2.1.1.1 Key data from secondary sources 30
2.1.2 PRIMARY DATA 30
2.1.2.1 Primary sources 31
2.1.2.2 Key data from primary sources 32
2.1.2.3 Key industry insights 33
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 34
2.2 MARKET SIZE ESTIMATION 34
2.2.1 BOTTOM-UP APPROACH 34
FIGURE 5 REVENUE SHARE ANALYSIS 35
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 36
2.2.2 TOP-DOWN APPROACH 37
FIGURE 7 CONTRAST MEDIA MARKET: TOP-DOWN APPROACH 37
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 38
FIGURE 8 DATA TRIANGULATION METHODOLOGY 38
2.4 MARKET SHARE ANALYSIS 39
2.5 STUDY ASSUMPTIONS 39
2.5.1 MARKET ASSUMPTIONS 39
2.5.2 GROWTH RATE ASSUMPTIONS 39
2.6 RESEARCH LIMITATIONS 40
2.6.1 METHODOLOGY-RELATED LIMITATIONS 40
2.6.2 SCOPE-RELATED LIMITATIONS 40
2.7 RISK ASSESSMENT 40
TABLE 1 RISK ASSESSMENT ANALYSIS 40
2.8 RECESSION IMPACT 40
3 EXECUTIVE SUMMARY 41
FIGURE 9 CONTRAST MEDIA MARKET, BY TYPE, 2023 VS. 2029 (USD BILLION) 41
FIGURE 10 CONTRAST MEDIA MARKET, BY FORM, 2023 VS. 2029 (USD BILLION) 42
FIGURE 11 CONTRAST MEDIA MARKET, BY MODALITY, 2023 VS. 2029 (USD BILLION) 42
FIGURE 12 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2029 (USD BILLION) 43
FIGURE 13 CONTRAST MEDIA MARKET, BY INDICATION, 2023 VS. 2029 (USD BILLION) 43
FIGURE 14 CONTRAST MEDIA MARKET, BY APPLICATION, 2023 VS. 2029 (USD BILLION) 44
FIGURE 15 CONTRAST MEDIA MARKET, BY END USER, 2023 VS. 2029 (USD BILLION) 44
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CONTRAST MEDIA MARKET 45
4 PREMIUM INSIGHTS 46
4.1 CONTRAST MEDIA MARKET OVERVIEW 46
FIGURE 17 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 46
4.2 NORTH AMERICA: CONTRAST MEDIA MARKET, BY END USER & COUNTRY (2022) 47
FIGURE 18 HOSPITALS, CLINICS, & AMBULATORY SURGERY CENTERS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 47
4.3 CONTRAST MEDIA MARKET: REGIONAL MIX 47
FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 47
4.4 CONTRAST MEDIA MARKET: DEVELOPED VS. DEVELOPING MARKETS 48
FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 48
4.5 CONTRAST MEDIA MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
FIGURE 21 CHINA AND INDIA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 48
5 MARKET OVERVIEW 49
5.1 INTRODUCTION 49
5.2 MARKET DYNAMICS 49
FIGURE 22 CONTRAST MEDIA MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
5.2.1 DRIVERS 50
5.2.1.1 Rising prevalence of chronic diseases 50
TABLE 2 CANCER INCIDENCE, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 50
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2020 VS. 2030 VS. 2040 51
5.2.1.2 Growing number of approvals of contrast media 51
5.2.1.3 Rising volume of CT and MRI examinations performed 52
TABLE 4 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019–2021 52
TABLE 5 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2019–2021 53
5.2.1.4 Growing number of diagnostic centers and hospitals 53
5.2.1.5 Availability of reimbursement 54
5.2.1.6 Increasing demand for early disease diagnosis 54
5.2.1.7 Increasing funding by public-private organizations 55
TABLE 6 LIST OF BENEFICIARY HOSPITALS OF NHS WALES 55
5.2.2 RESTRAINTS 56
5.2.2.1 Side-effects and risks of allergic reactions associated with contrast media 56
TABLE 7 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Generic contrast media 57
5.2.3.2 Increasing research on contrast media 57
TABLE 8 INDICATIVE LIST OF RESEARCH STUDIES 58
5.2.3.3 Growth opportunities in emerging economies 58
5.2.3.4 Increasing demand for minimally invasive imaging procedures 59
5.2.4 CHALLENGES 59
5.2.4.1 Preference for alternative modalities of imaging that do not require contrast media 59
5.2.4.2 Restriction of linear gadolinium-based contrast media and product recalls 60
5.2.4.3 Dearth of trained professionals 61
TABLE 9 US: METROPOLITAN AREAS WITH HIGH EMPLOYMENT LEVELS FOR RADIOLOGY TECHNOLOGISTS AND TECHNICIANS, 2022 62
5.2.4.4 Shortage of contrast media 62
5.3 VALUE CHAIN ANALYSIS 63
FIGURE 23 VALUE CHAIN ANALYSIS: CONTRAST MEDIA MARKET 63
5.4 SUPPLY CHAIN ANALYSIS 64
FIGURE 24 SUPPLY CHAIN ANALYSIS: CONTRAST MEDIA MARKET 64
5.5 TECHNOLOGY ANALYSIS 65
5.6 PORTER’S FIVE FORCES ANALYSIS 65
5.6.1 THREAT OF NEW ENTRANTS 66
5.6.2 INTENSITY OF COMPETITIVE RIVALRY 66
5.6.3 BARGAINING POWER OF BUYERS 66
5.6.4 BARGAINING POWER OF SUPPLIERS 66
5.6.5 THREAT OF SUBSTITUTES 66
5.7 REGULATORY LANDSCAPE 66
TABLE 10 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING CONTRAST MEDIA MARKET 67
5.7.1 EU REGULATIONS 68
5.7.2 FDA REGULATIONS 68
5.7.3 JPMA REGULATIONS 69
5.8 PATENT ANALYSIS 69
FIGURE 25 PATENT ANALYSIS: IODINATED CONTRAST MEDIA 69
FIGURE 26 PATENT ANALYSIS: GADOLINIUM-BASED CONTRAST MEDIA 70
5.9 KEY CONFERENCES & EVENTS IN 2024–2025 71
TABLE 11 LIST OF CONFERENCES & EVENTS IN CONTRAST MEDIA MARKET 71
5.10 PRICING ANALYSIS 74
TABLE 12 AVERAGE SELLING PRICE OF CONTRAST MEDIA 74
5.11 TRADE ANALYSIS 75
TABLE 13 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018–2022 (USD MILLION) 75
TABLE 14 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS AND DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2018–2022 (USD MILLION) 75
5.12 ECOSYSTEM ANALYSIS 76
FIGURE 27 ECOSYSTEM ANALYSIS: CONTRAST MEDIA MARKET 76
TABLE 15 ROLE IN ECOSYSTEM 76
FIGURE 28 KEY PLAYERS OPERATING IN CONTRAST MEDIA MARKET 77
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 77
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 78
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 78
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 78
5.14.2 BUYING CRITERIA 79
FIGURE 30 KEY BUYING CRITERIA FOR TOP END USERS 79
TABLE 17 KEY BUYING CRITERIA FOR END USERS 79
6 CONTRAST MEDIA MARKET, BY TYPE 80
6.1 INTRODUCTION 81
TABLE 18 CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 81
6.2 IODINATED CONTRAST MEDIA 81
6.2.1 HIGH DEMAND FOR IODINATED CONTRAST MEDIA DUE TO HIGHER DOSAGE REQUIRED IN CT SCANS—KEY FACTOR DRIVING MARKET GROWTH 81
TABLE 19 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 83
TABLE 20 IODINATED CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 83
6.3 GADOLINIUM-BASED CONTRAST MEDIA 84
6.3.1 SUSPICION REGARDING SAFETY PROFILE TO CHALLENGE MARKET GROWTH 84
TABLE 21 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 85
TABLE 22 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 85
6.4 MICROBUBBLE CONTRAST MEDIA 86
6.4.1 EXTREMELY POPULAR AMONG PHYSICIANS WORLDWIDE 86
TABLE 23 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 87
TABLE 24 MICROBUBBLE CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 87
6.5 BARIUM-BASED CONTRAST MEDIA 88
6.5.1 ADVERSE EFFECTS ASSOCIATED WITH USE TO NEGATIVELY IMPACT MARKET 88
TABLE 25 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 88
TABLE 26 BARIUM-BASED CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 89
7 CONTRAST MEDIA MARKET, BY FORM 90
7.1 INTRODUCTION 91
TABLE 27 CONTRAST MEDIA MARKET, BY FORM, 2021–2029 (USD MILLION) 91
7.2 LIQUID 91
7.2.1 INCREASING ADOPTION OF EASY-TO-USE LIQUID FORM OF CONTRAST MEDIA ACROSS HOSPITALS AND DIAGNOSTIC CENTERS TO DRIVE MARKET 91
TABLE 28 LIQUID CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 92
7.3 POWDER 92
7.3.1 EASE OF HANDLING, STORAGE, AND TRANSPORTATION TO FAVOR ADOPTION 92
TABLE 29 POWDER CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 93
7.4 OTHER FORMS 93
TABLE 30 CONTRAST MEDIA MARKET FOR OTHER FORMS, BY REGION, 2021–2029 (USD MILLION) 94
8 CONTRAST MEDIA MARKET, BY MODALITY 95
8.1 INTRODUCTION 96
TABLE 31 NUMBER OF PROCEDURES PERFORMED, BY MODALITY, 2017–2020 96
TABLE 32 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2021–2029 (MILLION LITERS) 96
TABLE 33 CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 96
8.2 X-RAY 97
8.2.1 PRODUCTION OF HIGH-QUALITY IMAGES TO DRIVE MARKET 97
TABLE 34 UK: NUMBER OF X-RAY TESTS PERFORMED, 2012–2020 97
TABLE 35 CONTRAST MEDIA MARKET FOR X-RAY, BY REGION, 2021–2029 (USD MILLION) 98
TABLE 36 CONTRAST MEDIA MARKET FOR X-RAY, BY COUNTRY, 2021–2029 (USD MILLION) 98
8.3 CT 99
8.3.1 INCREASING NUMBER OF CT EXAMINATIONS TO PROPEL MARKET 99
TABLE 37 NUMBER OF CT SCANNERS PER 1,000 INHABITANTS, BY COUNTRY, 2020 VS. 2021 99
TABLE 38 UK: NUMBER OF CT SCANS PERFORMED, 2012–2020 100
TABLE 39 CONTRAST MEDIA MARKET FOR CT, BY REGION, 2021–2029 (USD MILLION) 100
TABLE 40 CONTRAST MEDIA MARKET FOR CT, BY COUNTRY, 2021–2029 (USD MILLION) 101
8.4 MRI 101
8.4.1 ADVANTAGES OF MRI OVER OTHER IMAGING MODALITIES TO SUPPORT MARKET GROWTH 101
TABLE 41 NUMBER OF MRI UNITS PER 1,000 INHABITANTS, BY COUNTRY, 2019 VS. 2020 VS. 2021 103
TABLE 42 UK: NUMBER OF MRI TESTS PERFORMED, 2012–2020 103
TABLE 43 CONTRAST MEDIA MARKET FOR MRI, BY REGION, 2021–2029 (USD MILLION) 103
TABLE 44 CONTRAST MEDIA MARKET FOR MRI, BY COUNTRY, 2021–2029 (USD MILLION) 104
8.5 ULTRASOUND 104
8.5.1 FLEXIBLE AND LOW-COST DIAGNOSTIC IMAGING MODALITY–KEY FACTORS DRIVING MARKET GROWTH 104
TABLE 45 UK: NUMBER OF ULTRASOUND TESTS PERFORMED, 2012–2020 106
TABLE 46 CONTRAST MEDIA MARKET FOR ULTRASOUND, BY REGION, 2021–2029 (USD MILLION) 106
TABLE 47 CONTRAST MEDIA MARKET FOR ULTRASOUND, BY COUNTRY, 2021–2029 (USD MILLION) 107
9 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION 108
9.1 INTRODUCTION 109
TABLE 48 CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 109
9.2 INTRAVASCULAR ROUTE 109
9.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTE IN IMAGING MODALITIES TO DRIVE MARKET 109
9.2.1.1 Intravenous (IV) route 110
9.2.1.2 Intra-arterial (IA) route 110
TABLE 49 CONTRAST MEDIA MARKET FOR INTRAVASCULAR ROUTE, BY REGION, 2021–2029 (USD MILLION) 111
TABLE 50 CONTRAST MEDIA MARKET FOR INTRAVASCULAR ROUTE, BY COUNTRY, 2021–2029 (USD MILLION) 111
9.3 ORAL ROUTE 112
9.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN GIT, LEADING TO PERITONITIS 112
TABLE 51 CONTRAST MEDIA MARKET FOR ORAL ROUTE, BY REGION, 2021–2029 (USD MILLION) 112
TABLE 52 CONTRAST MEDIA MARKET FOR ORAL ROUTE, BY COUNTRY, 2021–2029 (USD MILLION) 113
9.4 RECTAL ROUTE 114
9.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH 114
TABLE 53 CONTRAST MEDIA MARKET FOR RECTAL ROUTE, BY REGION, 2021–2029 (USD MILLION) 114
TABLE 54 CONTRAST MEDIA MARKET FOR RECTAL ROUTE, BY COUNTRY, 2021–2029 (USD MILLION) 115
9.5 OTHER ROUTES 115
TABLE 55 CONTRAST MEDIA MARKET FOR OTHER ROUTES, BY REGION, 2021–2029 (USD MILLION) 116
TABLE 56 CONTRAST MEDIA MARKET FOR OTHER ROUTES, BY COUNTRY, 2021–2029 (USD MILLION) 116
10 CONTRAST MEDIA MARKET, BY INDICATION 117
10.1 INTRODUCTION 118
TABLE 57 CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 118
10.2 CARDIOVASCULAR DISEASE 118
10.2.1 HIGH BURDEN OF CVD TO DRIVE MARKET 118
TABLE 58 CONTRAST MEDIA MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2029 (USD MILLION) 119
TABLE 59 CONTRAST MEDIA MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2029 (USD MILLION) 120
10.3 CANCER 120
10.3.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO HIGH CANCER PREVALENCE IN REGION 120
TABLE 60 CANCER INCIDENCE, BY REGION, 2020 VS. 2035 (MILLION) 121
TABLE 61 CONTRAST MEDIA MARKET FOR CANCER, BY REGION, 2021–2029 (USD MILLION) 121
TABLE 62 CONTRAST MEDIA MARKET FOR CANCER, BY COUNTRY, 2021–2029 (USD MILLION) 122
10.4 GASTROINTESTINAL DISORDERS 122
10.4.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH 122
TABLE 63 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2029 (USD MILLION) 123
TABLE 64 CONTRAST MEDIA MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION) 123
10.5 MUSCULOSKELETAL DISORDERS 124
10.5.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH 124
TABLE 65 CONTRAST MEDIA MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2029 (USD MILLION) 125
TABLE 66 CONTRAST MEDIA MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION) 125
10.6 NEUROLOGICAL DISORDERS 126
10.6.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET 126
TABLE 67 CONTRAST MEDIA MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2029 (USD MILLION) 127
TABLE 68 CONTRAST MEDIA MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION) 127
10.7 NEPHROLOGICAL DISORDERS 128
10.7.1 RISING PREVALENCE OF ESRD TO DRIVE DEMAND FOR DIAGNOSTIC TOOLS 128
TABLE 69 CONTRAST MEDIA MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2021–2029 (USD MILLION) 128
TABLE 70 CONTRAST MEDIA MARKET FOR NEPHROLOGICAL DISORDERS, BY COUNTRY, 2021–2029 (USD MILLION) 129
11 CONTRAST MEDIA MARKET, BY APPLICATION 130
11.1 INTRODUCTION 131
TABLE 71 CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 131
11.2 RADIOLOGY 131
11.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE MARKET 131
TABLE 72 CONTRAST MEDIA MARKET FOR RADIOLOGY, BY REGION, 2021–2029 (USD MILLION) 132
TABLE 73 CONTRAST MEDIA MARKET FOR RADIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 133
11.3 INTERVENTIONAL RADIOLOGY 134
11.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH 134
TABLE 74 CONTRAST MEDIA MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2021–2029 (USD MILLION) 134
TABLE 75 CONTRAST MEDIA MARKET FOR INTERVENTIONAL RADIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 135
11.4 INTERVENTIONAL CARDIOLOGY 135
11.4.1 RISING INCIDENCE OF CARDIAC DISEASES TO DRIVE MARKET 135
TABLE 76 CONTRAST MEDIA MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2021–2029 (USD MILLION) 136
TABLE 77 CONTRAST MEDIA MARKET FOR INTERVENTIONAL CARDIOLOGY, BY COUNTRY, 2021–2029 (USD MILLION) 137
12 CONTRAST MEDIA MARKET, BY END USER 138
12.1 INTRODUCTION 139
TABLE 78 CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 139
12.2 HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS 139
12.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES TO DRIVE MARKET 139
TABLE 79 CONTRAST MEDIA MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2021–2029 (USD MILLION) 140
TABLE 80 CONTRAST MEDIA MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021–2029 (USD MILLION) 141
12.3 DIAGNOSTIC IMAGING CENTERS 141
12.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO PROPEL MARKET 141
TABLE 81 CONTRAST MEDIA MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2021–2029 (USD MILLION) 142
TABLE 82 CONTRAST MEDIA MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2021–2029 (USD MILLION) 143
13 CONTRAST MEDIA MARKET, BY REGION 144
13.1 INTRODUCTION 145
TABLE 83 CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 145
13.2 NORTH AMERICA 146
FIGURE 31 NORTH AMERICA: CONTRAST MEDIA MARKET SNAPSHOT 146
TABLE 84 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 147
TABLE 85 NORTH AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 147
TABLE 86 NORTH AMERICA: CONTRAST MEDIA MARKET, BY FORM, 2021–2029 (USD MILLION) 147
TABLE 87 NORTH AMERICA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 148
TABLE 88 NORTH AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 148
TABLE 89 NORTH AMERICA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 149
TABLE 90 NORTH AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 149
TABLE 91 NORTH AMERICA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 149
13.2.1 US 150
13.2.1.1 Rising incidence of chronic diseases to drive market 150
TABLE 92 US: KEY MACROINDICATORS 151
TABLE 93 US: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 151
TABLE 94 US: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 152
TABLE 95 US: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 152
TABLE 96 US: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 152
TABLE 97 US: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 153
TABLE 98 US: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 153
13.2.2 CANADA 153
13.2.2.1 Increasing investments in improving medical imaging to drive market 153
TABLE 99 CANADA: KEY MACROINDICATORS 154
TABLE 100 CANADA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 155
TABLE 101 CANADA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 155
TABLE 102 CANADA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 156
TABLE 103 CANADA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 156
TABLE 104 CANADA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 157
TABLE 105 CANADA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 157
13.2.3 RECESSION IMPACT ON NORTH AMERICAN CONTRAST MEDIA MARKET 157
13.3 EUROPE 158
TABLE 106 EUROPE: NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, BY COUNTRY, 2021 158
TABLE 107 EUROPE: NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, BY COUNTRY, 2021 158
TABLE 108 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 158
TABLE 109 EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 159
TABLE 110 EUROPE: CONTRAST MEDIA MARKET, BY FORM, 2021–2029 (USD MILLION) 159
TABLE 111 EUROPE: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 159
TABLE 112 EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 160
TABLE 113 EUROPE: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 160
TABLE 114 EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 161
TABLE 115 EUROPE: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 161
13.3.1 GERMANY 161
13.3.1.1 Presence of well-developed diagnostic imaging infrastructure to support market growth 161
TABLE 116 GERMANY: KEY MACROINDICATORS 162
TABLE 117 GERMANY: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 118 GERMANY: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 163
TABLE 119 GERMANY: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 163
TABLE 120 GERMANY: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 164
TABLE 121 GERMANY: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 164
TABLE 122 GERMANY: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 164
13.3.2 FRANCE 165
13.3.2.1 Increasing prevalence of cancer to propel market 165
TABLE 123 FRANCE: KEY MACROINDICATORS 165
TABLE 124 FRANCE: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 166
TABLE 125 FRANCE: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 166
TABLE 126 FRANCE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 167
TABLE 127 FRANCE: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 167
TABLE 128 FRANCE: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 168
TABLE 129 FRANCE: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 168
13.3.3 UK 168
13.3.3.1 Increasing investments in diagnostic imaging to boost market growth 168
TABLE 130 UK: KEY MACROINDICATORS 170
TABLE 131 UK: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 170
TABLE 132 UK: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 170
TABLE 133 UK: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 171
TABLE 134 UK: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 171
TABLE 135 UK: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 172
TABLE 136 UK: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 172
13.3.4 ITALY 172
13.3.4.1 Rising geriatric population to drive demand for diagnostic procedures 172
TABLE 137 ITALY: KEY MACROINDICATORS 173
TABLE 138 ITALY: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 173
TABLE 139 ITALY: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 174
TABLE 140 ITALY: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 174
TABLE 141 ITALY: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 175
TABLE 142 ITALY: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 175
TABLE 143 ITALY: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 175
13.3.5 SPAIN 176
13.3.5.1 Shortage of radiologists to restrain market growth 176
TABLE 144 SPAIN: KEY MACROINDICATORS 176
TABLE 145 SPAIN: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 177
TABLE 146 SPAIN: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 177
TABLE 147 SPAIN: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 178
TABLE 148 SPAIN: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 178
TABLE 149 SPAIN: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 179
TABLE 150 SPAIN: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 179
13.3.6 REST OF EUROPE 179
TABLE 151 REST OF EUROPE: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY, 2021 VS. 2022 180
TABLE 152 REST OF EUROPE: NUMBER OF MRI AND CT UNITS AND SCANS, BY COUNTRY, 2021 181
TABLE 153 REST OF EUROPE: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 181
TABLE 154 REST OF EUROPE: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 181
TABLE 155 REST OF EUROPE: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 182
TABLE 156 REST OF EUROPE: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 182
TABLE 157 REST OF EUROPE: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 183
TABLE 158 REST OF EUROPE: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 183
13.3.7 RECESSION IMPACT ON EUROPEAN CONTRAST MEDIA MARKET 183
13.4 ASIA PACIFIC 184
FIGURE 32 ASIA PACIFIC: CONTRAST MEDIA MARKET SNAPSHOT 184
TABLE 159 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 185
TABLE 160 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 185
TABLE 161 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY FORM, 2021–2029 (USD MILLION) 185
TABLE 162 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 186
TABLE 163 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 186
TABLE 164 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 186
TABLE 165 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 187
TABLE 166 ASIA PACIFIC: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 187
13.4.1 CHINA 187
13.4.1.1 High incidence of cancer and stroke to support market growth 187
TABLE 167 CHINA: KEY MACROINDICATORS 188
TABLE 168 CHINA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 188
TABLE 169 CHINA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 189
TABLE 170 CHINA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 189
TABLE 171 CHINA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 189
TABLE 172 CHINA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 190
TABLE 173 CHINA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 190
13.4.2 JAPAN 190
13.4.2.1 Strong healthcare sector and high disease incidence to favor market growth 190
TABLE 174 JAPAN: KEY MACROINDICATORS 191
TABLE 175 JAPAN: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 191
TABLE 176 JAPAN: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 192
TABLE 177 JAPAN: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 192
TABLE 178 JAPAN: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 192
TABLE 179 JAPAN: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 193
TABLE 180 JAPAN: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 193
13.4.3 INDIA 193
13.4.3.1 Growing investments in radiology to propel market growth 193
TABLE 181 INDIA: KEY MACROINDICATORS 194
TABLE 182 INDIA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 195
TABLE 183 INDIA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 195
TABLE 184 INDIA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 196
TABLE 185 INDIA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 196
TABLE 186 INDIA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 197
TABLE 187 INDIA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 197
13.4.4 AUSTRALIA 197
13.4.4.1 Increasing research activities to drive market 197
TABLE 188 AUSTRALIA: KEY MACROINDICATORS 198
TABLE 189 AUSTRALIA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 199
TABLE 190 AUSTRALIA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 199
TABLE 191 AUSTRALIA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 199
TABLE 192 AUSTRALIA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 200
TABLE 193 AUSTRALIA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 200
TABLE 194 AUSTRALIA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 201
13.4.5 REST OF ASIA PACIFIC 201
TABLE 195 NUMBER OF MRI AND CT UNITS PER MILLION POPULATION, BY COUNTRY, 2021 202
TABLE 196 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 202
TABLE 197 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 202
TABLE 198 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 203
TABLE 199 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 203
TABLE 200 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 204
TABLE 201 REST OF ASIA PACIFIC: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 204
13.4.6 RECESSION IMPACT ON ASIA PACIFIC CONTRAST MEDIA MARKET 204
13.5 REST OF THE WORLD 205
TABLE 202 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY REGION, 2021–2029 (USD MILLION) 205
TABLE 203 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 205
TABLE 204 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY FORM, 2021–2029 (USD MILLION) 206
TABLE 205 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 206
TABLE 206 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 206
TABLE 207 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 207
TABLE 208 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 207
TABLE 209 REST OF THE WORLD: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 208
13.5.1 LATIN AMERICA 208
13.5.1.1 Lack of adequate healthcare infrastructure and poor insurance coverage to limit market growth 208
TABLE 210 LATIN AMERICA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 209
TABLE 211 LATIN AMERICA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 209
TABLE 212 LATIN AMERICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 209
TABLE 213 LATIN AMERICA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 210
TABLE 214 LATIN AMERICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 210
TABLE 215 LATIN AMERICA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 210
13.5.2 MIDDLE EAST & AFRICA 211
13.5.2.1 High burden of chronic diseases to drive market 211
TABLE 216 ISRAEL: DIAGNOSTIC IMAGING DATA, 2022 211
TABLE 217 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 212
TABLE 218 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 212
TABLE 219 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 213
TABLE 220 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 213
TABLE 221 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 214
TABLE 222 MIDDLE EAST & AFRICA: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 214
13.5.3 GCC COUNTRIES 214
13.5.3.1 Increasing government investments in healthcare sector and growing pharmaceuticals industry to drive market 214
TABLE 223 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY TYPE, 2021–2029 (USD MILLION) 215
TABLE 224 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY MODALITY, 2021–2029 (USD MILLION) 215
TABLE 225 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY ROUTE OF ADMINISTRATION, 2021–2029 (USD MILLION) 216
TABLE 226 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY INDICATION, 2021–2029 (USD MILLION) 216
TABLE 227 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY APPLICATION, 2021–2029 (USD MILLION) 217
TABLE 228 GCC COUNTRIES: CONTRAST MEDIA MARKET, BY END USER, 2021–2029 (USD MILLION) 217
13.5.4 RECESSION IMPACT ON REST OF THE WORLD CONTRAST MEDIA MARKET 217
14 COMPETITIVE LANDSCAPE 218
14.1 OVERVIEW 218
14.2 STRATEGIES ADOPTED BY KEY PLAYERS 218
TABLE 229 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRAST MEDIA MARKET 219
14.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 220
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CONTRAST MEDIA MARKET 220
14.4 MARKET SHARE ANALYSIS 220
TABLE 230 CONTRAST MEDIA MARKET: DEGREE OF COMPETITION 221
FIGURE 34 CONTRAST MEDIA MARKET SHARE, BY KEY PLAYER (2022) 221
14.5 COMPANY EVALUATION MATRIX 222
14.5.1 STARS 222
14.5.2 EMERGING LEADERS 222
14.5.3 PERVASIVE PLAYERS 223
14.5.4 PARTICIPANTS 223
FIGURE 35 CONTRAST MEDIA MARKET: COMPANY EVALUATION MATRIX, 2022 223
14.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS 224
TABLE 231 FOOTPRINT ANALYSIS 224
TABLE 232 TYPE FOOTPRINT 224
TABLE 233 REGIONAL FOOTPRINT 225
14.6 STARTUP/SME EVALUATION MATRIX 226
14.6.1 PROGRESSIVE COMPANIES 226
14.6.2 RESPONSIVE COMPANIES 226
14.6.3 DYNAMIC COMPANIES 226
14.6.4 STARTING BLOCKS 226
FIGURE 36 CONTRAST MEDIA MARKET: STARTUP/SME EVALUATION MATRIX, 2022 227
14.7 COMPETITIVE BENCHMARKING 228
TABLE 234 CONTRAST MEDIA MARKET: KEY STARTUPS/SMES 228
14.8 COMPETITIVE SCENARIO 228
14.8.1 PRODUCT LAUNCHES & APPROVALS 228
TABLE 235 CONTRAST MEDIA MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–DECEMBER 2023 229
14.8.2 DEALS 230
TABLE 236 CONTRAST MEDIA MARKET: DEALS, JANUARY 2020–DECEMBER 2023 230
14.8.3 OTHER DEVELOPMENTS 231
TABLE 237 CONTRAST MEDIA MARKET: OTHER DEVELOPMENTS, JANUARY 2020–DECEMBER 2023 231
14.9 BRAND/PRODUCT COMPARISON: CONTRAST MEDIA MARKET 231
TABLE 238 BRAND/PRODUCT COMPARISON (IODINATED CONTRAST MEDIA) 231
TABLE 239 BRAND/PRODUCT COMPARISON (GADOLINIUM-BASED CONTRAST MEDIA) 231
15 COMPANY PROFILES 232
(Business overview, Products offered, Recent developments & MnM View)*
15.1 KEY PLAYERS 232
15.1.1 GE HEALTHCARE 232
TABLE 240 GE HEALTHCARE: BUSINESS OVERVIEW 232
FIGURE 37 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 233
15.1.2 BRACCO IMAGING SPA 236
TABLE 241 BRACCO IMAGING SPA: BUSINESS OVERVIEW 236
15.1.3 BAYER AG 240
TABLE 242 BAYER AG: BUSINESS OVERVIEW 240
FIGURE 38 BAYER AG: COMPANY SNAPSHOT (2022) 240
15.1.4 GUERBET 243
TABLE 243 GUERBET: BUSINESS OVERVIEW 243
FIGURE 39 GUERBET: COMPANY SNAPSHOT (2022) 243
15.1.5 LANTHEUS MEDICAL IMAGING 247
TABLE 244 LANTHEUS MEDICAL IMAGING: BUSINESS OVERVIEW 247
FIGURE 40 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2022) 247
15.1.6 UNIJULES LIFE SCIENCES LTD. 249
TABLE 245 UNIJULES LIFE SCIENCES LTD.: BUSINESS OVERVIEW 249
15.1.7 J.B. CHEMICALS & PHARMACEUTICALS LIMITED 251
TABLE 246 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: BUSINESS OVERVIEW 251
FIGURE 41 J.B. CHEMICALS & PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023) 251
15.1.8 SANOCHEMIA PHARMAZEUTIKA 253
TABLE 247 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW 253
15.1.9 TAEJOON PHARM CO., LTD. 254
TABLE 248 TAEJOON PHARM CO., LTD.: BUSINESS OVERVIEW 254
15.1.10 JODAS EXPOIM 255
TABLE 249 JODAS EXPOIM: BUSINESS OVERVIEW 255
15.1.11 IMAX DIAGNOSTIC IMAGING LIMITED 257
TABLE 250 IMAX DIAGNOSTIC IMAGING LIMITED: BUSINESS OVERVIEW 257
15.1.12 YANGTZE RIVER PHARMACEUTICAL GROUP 258
TABLE 251 YANGTZE RIVER PHARMACEUTICAL GROUP: BUSINESS OVERVIEW 258
15.1.13 LIVEALTH BIOPHARMA 259
TABLE 252 LIVEALTH BIOPHARMA PVT. LTD.: BUSINESS OVERVIEW 259
15.1.14 BEIJING BEILU PHARMACEUTICAL CO., LTD. 260
TABLE 253 BEIJING BEILU PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW 260
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
15.2 OTHER PLAYERS 262
15.2.1 UNISPIRE BIOPHARMA PRIVATE LIMITED 262
15.2.2 ARCO LIFESCIENCES (I) PVT. LTD. 263
15.2.3 STANEX DRUGS & CHEMICALS PVT. LTD. 264
15.2.4 REGE IMAGING & CINE FILMS PRIVATE LIMITED 265
15.2.5 K DIAM EXIM 265
15.2.6 ONKO İLAÇ SAN. VE TIC. A.Ş. 266
15.2.7 FRESENIUS KABI 267
15.2.8 BIEM İLAÇ SAN. VE TIC. A.Ş. 268
15.2.9 ADVACARE PHARMA 269
16 APPENDIX 270
16.1 DISCUSSION GUIDE 270
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 275
16.3 CUSTOMIZATION OPTIONS 277
16.4 RELATED REPORTS 277
16.5 AUTHOR DETAILS 278